{"url_path":"/sec/cnta/8-k/2026-06-24/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1847903/0001193125-26-280337-index.html","accession_number":"0001193125-26-280337","cik":"0001847903","ticker":"CNTA","issuer_name":"Centessa Pharmaceuticals plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1847903/0001193125-26-280337-index.html","primary_entity_key":"0001847903","primary_entity_name":"Centessa Pharmaceuticals plc"},"word_count":153,"has_tables":true,"body_markdown":"Item 3.01\n\nNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.\n\nIn connection with the completion of the Acquisition, Centessa requested that The Nasdaq Stock Market LLC (“Nasdaq”) (a) halt trading of the Company ADSs effective as of 8:00 p.m. New York City time on June 23, 2026 and (b) file with the Securities and Exchange Commission (the “SEC”) a Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on Form 25 to delist the Company ADSs. Upon effectiveness of such Form 25, a Certification and Notice of Termination of Registration on Form 15 under the Exchange Act, requesting that the Company ADSs be deregistered and that Centessa’s reporting obligations under Sections 13(a) and 15(d) of the Exchange Act be suspended with respect to the Company ADSs will be filed with the SEC."}